DR MAHA OTHMAN (Orcid ID: 0000-0001-7562-203X)
ALAN PARKER (Orcid ID: 0000-0002-9302-1761)

Article type: Forum

To Clot or Not to Clot? Ad is the Question - Insights on Mechanisms Related to Vaccine Induced Thrombotic Thrombocytopenia

Maha Othman¹,², Alexander T Baker³,⁴, Elena Gupalo⁵, Abdelrahman Elsebaie¹, Carly M. Bliss⁴, Matthew T. Rondina⁶,⁷, David Lillicrap⁸, Alan L. Parker⁴

1. Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
2. School of Baccalaureate Nursing, St Lawrence College, Kingston, Ontario, Canada
3. Center for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, USA
4. Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK
5. National Medical Research Center for Cardiology, Moscow, Russia
6. Departments of Internal Medicine and Pathology, and the Molecular Medicine Program, University of Utah Health, Salt Lake City, Utah, USA.
7. Department of Internal Medicine and GRECC, George E. Wahlen VAMC, Salt Lake City, Utah, USA.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/JTH.15485

This article is protected by copyright. All rights reserved
Abstract

Vaccine-induced immune thrombotic thrombocytopenia (VITT) has caused global concern. VITT is characterized by thrombosis and thrombocytopenia following COVID-19 vaccinations with the AstraZeneca ChAdOx1 nCov-19 and the Janssen Ad26.COV2.S vaccines. Patients present with thrombosis, severe thrombocytopenia developing 5 to 24 days following first dose of vaccine, with elevated D-dimer, and PF4 antibodies, signifying platelet activation. As of June 1, 2021, over 1.93 billion COVID-19 vaccine doses had been administered worldwide. Currently, 467 VITT cases (0.000024%) have been reported across the UK, Europe, Canada and Australia. Guidance on diagnosis and management of VITT has been reported but the pathogenic mechanism is yet to be fully elucidated. Here, we propose and discuss potential mechanisms in relation to adenovirus induction of VITT. We provide
insights and clues into areas warranting investigation into the mechanistic basis of VITT, highlighting the unanswered questions. Further research is required to help solidify a pathogenic model for this condition.

**Key Words:**
- Adenovirus
- Platelet activation
- Thrombosis
- COVID-19 Vaccine
- Thrombocytopenia

**Disclosure:** All authors have no conflicts of interest
Introduction- What is known about VITT?
The novel, and rare, syndrome termed Vaccine-induced immune thrombotic thrombocytopenia (VITT), or thrombotic thrombocytopenic syndrome (TTS), has caused global concern among physicians, researchers, and the public alike. VITT is characterized by thrombosis and thrombocytopenia occurring following COVID-19 vaccinations and, so far, only reported following treatment with the AstraZeneca ChAdOx1 nCov-19 and the Janssen Ad26.COV2.S vaccines. The clinical features of VITT include thrombosis, commonly cerebral venous sinus thrombosis (CVST) (but many patients had other non-CVST thromboses with several exhibiting concurrent thromboses at other sites) [1,2], and severe thrombocytopenia (median platelet counts 20,000 to 30,000) developing 5 to 24 days following the first dose of the vaccine, together with elevated D-dimer. A hallmark of VITT patients is the presence of antibodies specific to platelet factor 4 (PF4), signifying platelet activation. This autoimmune element in VITT mimics autoimmune heparin-induced thrombocytopenia (aHIT) [3] also known as HIT/T [4] or HIT, a thrombocytopenic disorder caused by the formation of immunoglobulin G (IgG) antibodies against platelet-factor 4 (PF4) upon exposure to heparin [5, 6] or more precisely “spontaneous/autoimmune HIT” where there is no prior heparin exposure [7, 8].

Previous work has shown that aHIT patients express several classes of anti-PF4 antibodies. Group 1 only weakly binds to the PF4/Heparin complex and is not capable of causing aggregation and activation of platelets. Group 2 can aggregate PF4 in complex with heparin, leading to platelet activation via FcyRIIa. Group 3 binds most strongly and can aggregate PF4 in the absence of heparin or other polyanions [9]. It has been observed that non-platelet activating anti-PF4/Heparin antibodies occur in COVID-19 patients despite no prior heparin treatment [10]. However, VITT patients reported to date all tested positive for a particularly strong antibody type which is capable of binding to PF4 in the absence of heparin, mimicking aHIT [10]. The kinetics of PF4 antibodies in VITT in comparison to HIT is currently unknown and require further studies. Thus far, the suggested treatment paradigm has been to treat VITT similarly to HIT. This involves discontinuing heparin-based therapies and switching to
an alternative, non-heparin based, anti-thrombin inhibitor. Treatment with high dose intravenous immunoglobulin (IVIG), which act as a competitive inhibitor of IgG associated with FcγRIIa on the platelet surface, has also been used in VITT patients, with positive outcomes, reducing platelet activation and coagulation. ISTH guidance on diagnosis and management of VITT has been reported [11].

It is difficult to determine the exact incidence of this adverse effect but thus far it remains extremely low. As of June 1, 2021, over 1.93 billion COVID-19 vaccine doses had been administered worldwide [12]. Currently, a total of 467 VITT cases (0.000024%) have been reported across the United Kingdom (UK), Northern Europe, Canada and Australia, however, more cases are continuing to be reported [13-18]. As of June 1, 2021, the estimated incidence rate of VITT, based on the total number of first doses vaccinations (not exclusively AstraZeneca), is approximately 0.00086%, 0.000127%, 0.00028% and 0.000087% in the UK, Canada, Australia and central Europe, respectively [13-19]. Recent work has shown, robustly, that that incidence rate of VITT in recipients of the ChAdOx1 vaccine is in excess of the general population, and that similar effects are not seen in recipients of the BioNTech mRNA vaccine [20], although thrombocytopenia (without thrombosis) has been shown with BNT162b2 [21]. Whether similar incidence rates are observed in other populations with different genetic backgrounds remains to be seen.

The pathogenic mechanism of VITT remains to be verified, but thus far all evidence suggests a role for the vaccine material. Experimentation has demonstrated that the IgG antibodies that recognize PF4 activate platelets through their Fcγ-receptor IIA (FcγRIIA). This has been validated by ELISA testing [5, 6, 13]. However, it remains unclear what triggers production of these antibodies. The fact that VITT, so far, has been described only in association with adenoviral vector-based DNA virus vaccines, but not mRNA/lipid-based vaccines, raises the question of whether the syndrome is linked to the vector or other constituents in the vaccine preparation.
Herein, we discuss and analyze adenovirus immunogenicity and its interaction with platelets and other host proteins. We review aspects of the respective adenoviruses to provide clues on areas warranting investigation into the mechanistic basis of VITT, highlight several unanswered questions and discuss the potential pathogenic mechanisms involved.

**Adenovirus as a popular candidate for COVID-19 vaccination**

Adenovirus has been a popular and powerful therapeutic as a gene delivery vehicle. However, its value is restricted by the limited duration of transgene expression, typically 7-10 days. The intense overexpression of transgene, resulting in robust antigen specific responses [22], ease of manipulation of their double stranded DNA genome compared to RNA viruses, and the ability to scale up capacity to high titers [23] make it an attractive candidate as a vaccine platform.

Despite the broad phylogenetic tree of human adenoviruses, preclinical and clinical development of adenoviruses have focused, largely, on just one serotype – the species C serotype 5 (Ad5). Ad5 is known to induce potent antigen-specific T cell responses against the delivered transgenes, which makes it a compelling candidate as a vaccine [24]. However, clinical trials of Ad5 based vaccines have a chequered history with limited evidence that their use results in protective immunity [25, 26]. The results of the Ad5 based HIV STEP trial indicated that widespread pre-existing anti-Ad5 immunity in the population, amongst other variables, was associated with lack of efficacy from the vaccine [27]. These studies indicate how high seroprevalence hampers efficacy of Ad5 based vaccines. This prompted a switch towards exploring the diversity within the human adenovirus phylogenetic tree, as well as adenoviruses of non-human origin, to develop efficacious adenovirus-based vaccines with low or zero seroprevalence rates in the human population.

From the diverse phylogenetic tree, encompassing >100 human adenoviruses, and >100 closely related members including those of simian origin (http://hadvwg.gmu.edu/), two have emerged as leading candidates, critical in curtailing the 2019 SARS-CoV-2 pandemic – namely that based on species D human adenovirus serotype 26 (Ad26, developed by
Janssen Ltd) and that derived from the chimpanzee adenovirus isolate Y25 (developed by the Jenner Institute), also termed ChAdOx1, which is phylogenetically close to Ad4, though the hexon and fiber proteins display homology to their counterparts in species D and C, respectively. Both vaccine platforms have been widely clinically evaluated, for several indications, prior to the 2019 SARS-CoV-2 pandemic and demonstrated a robust ability to induce T-cell and antibody responses against a wide range of antigens [28, 29]. In terms of side effects, early phase clinical trials of both viral vector backbones have generally shown mild/moderate adverse events (AEs), limited to transient local and systemic events, with no serious vaccine-related AEs reported [30, 31]. This positive safety profile coupled with their ability to induce durable and robust antibody and T cell responses have made both Ad26 and ChAdOx1 obvious front runners in the race to develop SARS-CoV-2 vaccines to mitigate the COVID-19 pandemic.

**Adenovirus triggers platelet activation and promote blood clotting**

Adenovirus-platelet interactions deserve close attention due to the thrombocytopenia consistently reported following its' intravenous administration, whilst noting that thromboembolic events have not been observed previously and that COVID-19 vaccine is administered intramuscularly [32-34]. Experimental data shows that thrombocytopenia occurs 5-24-hours following intravenous administration of adenovirus to mice [35]. Thrombocytopenia is a well-known complication of various viral infections in humans. Multiple mechanisms have been proposed. These include increased nonspecific destruction of platelets caused by the deposition of circulating immune complexes on their surface, the appearance of specific antiplatelet antibodies, a decrease in platelet production, a direct effect of viruses on megakaryopoiesis, or a direct interaction between platelets and viruses [36, 37]. These interactions may be a part of platelets’ complex role in host defense processes. It is plausible the host defense role requires platelets to be activated to remove microbes, since activated platelets are cleared from circulation by the reticuloendothelial system [38, 39]. The addition of adenovirus to platelet rich plasma (PRP) in vitro leads to
spontaneous ADP- and ristocetin-induced platelet aggregation, P-selectin and CD41a expression on the platelet surface. The latter are two markers of platelet activation [40, 41]. Increased P-selectin in platelet and leukocyte-derived microparticle release is also observed following intravenous adenovirus (Ad5) injection in mice. This in turn triggers the formation of platelet-leukocyte aggregates that adhere and roll on the endothelium [35]. A crucial role of von Willebrand factor (VWF) in mediating thrombocytopenia was shown during in vivo experiments. This role is based on the high levels of VWF seen in the plasma and the appearance of ultra-large molecular weight VWF multimer (UL-VWF) following adenovirus injection in mice [35] and in Rhesus macaques [34]. This is further supported by the fact that thrombocytopenia was not significant when the virus was injected into VWF KO mice [35]. Adenovirus infection can stimulate a series of platelet responses, including platelet binding and internalization. However, the kinetics of the platelet activation and which components of platelets involved in the internalization process remain unclear. Virus particles were found in association with the cell surface and are localized to the open canalicular system as shown by electron microscopy [40]. Ad5 attachment to the cell surface requires binding of the fiber knob protein to coxsackie and adenovirus receptor (CAR) [42] but it is unclear if this is a requirement for platelet attachment. One study indicated that ~3.5 ± 1.9% of resting human platelets express Coxsackie and Adenovirus (CAR) which is dominantly localized within intracellular aggregates at sites of cell-cell contacts [43]. This indicates that CAR expression might be upregulated in response to platelet activation [43]. In addition to CAR, adenoviruses use a number of proteins and adhesion molecules that act as "co-receptors" and facilitate cell internalization. It has been shown that Ad5 interacts with members of the αV-integrin family – αVβ3 [44] and αVβ5 [45] – via the RGD-motif containing penton base protein [46]. Dual inhibition of αIIbβ3 and αVβ3 by Kistrin, a potent protein inhibitor of platelet aggregation and fibrinogen endocytosis, does not prevent adenovirus platelet coupling or virus internalization in vitro [40] indicating additional receptor binding partners may be able to facilitate internalization [47]. Despite unchanged internalization, the use of Kistrin leads to a decrease in platelet activation. A possible explanation is the existence of two independent processes, one leads to platelet activation following adenovirus administration and the other
to virus uptake. One can speculate that adenovirus-platelet binding does not always result in virus internalization with its subsequent clearance from the bloodstream. This hypothesis is supported by the fact that very little platelet-associated virus was found \textit{in vivo} in the blood of cancer patients treated intravenously with oncolytic adenovirus, and \textit{in vitro} experiments where whole blood was incubated with the studied adenoviruses [48]. It is possible that activation is a prerequisite for platelets to play their role in host defense process.

It is important to note the above effects apply to blood borne, replicating, viruses, rather than replication incompetent vectors such as in the vaccines. While adenovirus-based vaccinations are generally delivered intramuscularly, rather than intravenously, it would seem likely that small quantities of vector will enter the blood via leaky vasculature or capillary injuries at the injection site. Therefore, it is plausible that some adenovirus vector might be able to interact with blood and endothelial cells.

\textbf{Adenovirus interactions with host proteins}

The chimpanzee Y25 isolate, now known commonly as the ChAdOx1 vector, maps phylogenetically as closely related to the human adenovirus species E [49]. The sole human adenovirus member of this species, Ad4, is highly homologous to ChAdOx1, and is thought to have crossed over from chimps in a zoonotic event in the past [50, 51]. Adenovirus zoonosis events appear to be exceptionally rare, though they do have precedent. Cross species transmission of Titi monkey adenovirus was observed to cause infection in at least two humans, of which one was an animal handler [52]. Adenovirus, especially Ad4, has been associated with occasional but serious outbreaks amongst military recruits [53], and as such an unattenuated, replication competent, Ad4 vaccine has been delivered orally; a non-pathogenic route of delivery for this vector [54, 55]. Replication competent Ad4 vectors have also been evaluated in Phase 1 clinical testing as oral/intranasal vaccine vectors for influenza virus [56-58]. Oral vaccine vectors for anthrax [59] and intramuscular/intranasal vaccine vectors for HIV [60-62]. Ad4 has been shown to utilise CAR receptor, to gain cell entry [63]. Previous studies had hinted at this as an entry receptor for ChAdOx1 also [64], but a recent preprint demonstrates, using biological and structural studies, that ChAdOx1 can engage CAR as a primary cell attachment receptor, with a binding affinity similar to that
of Ad5 [65]. In the same study, CD46, a receptor used extensively used by species B1 adenoviruses, was observed to be unable to interact with ChAdOx1 fiber knob protein. Interactions involving other major entry receptors such as Desmoglein-2 (DSG-2) or sialic acid bearing glycans have not yet been excluded as possible receptors. In future it will also be important to investigate ChAdOx1’s co-receptor usage, such as integrins.

The major receptor usage of Ad26, a species D adenovirus, was clouded in controversy for many years. Initial infectivity studies using PBMCs from mice and humans suggested that CD46 was the major receptor used by Ad26 [66]. However, these conclusions were based upon data drawn from the transduction a small number of cells, yielding infection in only a fraction of cells even at high multiplicities of infection.

Recent, structural and biological studies have ruled out CD46 as an entry receptor engaged by the fiber knob protein of Ad26 (although a novel mechanism involving CD46 binding to the hexon protein has recently been proposed [67]). These studies demonstrate CAR is a receptor for Ad26, though the affinity of this interaction is reduced, compared to Ad5, by the presence of an extended loop in the fiber knob protein, which sterically inhibits CAR engagement [68]. Biologically, it is estimated that this steric clash reduces CAR affinity by around 15-fold compared to Ad5. Ad26 appears to have evolved a second receptor binding mechanism, attaching to sialic acid bearing glycans with high affinity [69]. This mechanism is tightly conserved by adenoviruses, like Ad26, that cause epidemic keratoconjunctivitis (EKC) [70]. An alternative mechanism of cell entry, involving αvβ3 integrin engagement has also been proposed [71], though engagement of integrins as co-receptors by the adenovirus penton base protein is well documented across all adenovirus species, with the exception of enteric species F adenoviruses (Ad40, Ad41) [72].

As well as their interactions with cellular receptors and co-receptors, adenoviruses are well documented to interact with a variety of proteins in the blood. One such interaction involves a high affinity interaction between the major adenovirus capsid protein, hexon, and
circulating blood clotting factor, FX [73-75]. For Ad5, this is documented as a high affinity, Ca\(^{2+}\) dependent interaction, which is responsible for efficient hepatic gene transfer of adenovirus, which transduces hepatocytes via heparan sulphate proteoglycan receptors (HSPGs) [74, 76]. This interaction can occur independently of FX activation status (i.e., FXa interacts with Ad5 equally as efficiently as FX), but does not result in the conversion of FX to FXa – either alone or in the presence of FVII and cells presenting tissue factor (Supplemental Figure 1). Furthermore, whilst the ability of ChAdOx1 to bind FX has not been assessed at the time of writing, it is known that Ad26 does not bind FX by the same mechanism [74, 77]. Ad5 hexon was shown to bind FVII in a subtly different way [78]. We previously demonstrated that protein C, FVII, FIX and FX (homologous domains) might bind and promote Ad5 uptake [79]. Prothrombin (Factor II) may also bind and compete with FX for hexon binding sites, though it lacks an SP domain, thus preventing interaction with HSPGs, which, for FX, is known to be mediated by a stretch of basic amino acids within the FX serine protease (SP) domain [80], which form a putative heparan binding exosite FX appears to be the major player in hepatic gene transfer. It is worth mentioning that FVII and FX may influence innate immunity and fibrosis in hepatic cells [81]. In addition to the well characterised interactions with blood clotting factors, interactions of adenovirus with complement proteins C3 [82] and CR1 [83], as well as von Willebrand factor and p-selectin [33] have all been described in the literature.

**VITT - Which vaccine?**

VITT has been observed following vaccination by both AstraZeneca’s ChAdOx1 nCoV-19 vaccine and the Janssen Ad26.COV2.S vaccine. At the time of writing, it has not been associated with non-adenoviral vector vaccinations, such as mRNA vaccines, as confirmed in a recent comparison of thrombotic events in recipients of ChAdOx1 and Pfizer/BioNTech vaccines [20]. Information is currently lacking on whether VITT is observed in recipients of other adenovirus vectored vaccines, such as the Sputnik V Ad5/Ad26 vaccine regimen administered, primarily, in Russia, or in recipients of the Ad5 vectored CanSino vaccine.
Proposed mechanisms for VITT

The primary and downstream mechanisms underpinning VITT are not currently understood, but the fact this side effect is clearly observed in the adenovirus-based formulations, warrants careful consideration and specific investigation. We herein, discuss the potential "smoking guns" in relation to adenovirus induction of VITT. We provide an illustration of the proposed mechanisms in Figure 1.

1- Direct activation of platelets following entry of adenovirus into the blood?

It is likely that small amounts of the adenovirus may enter the blood stream through capillary injuries resulting from the injection or leaky vasculature due to the inflammatory state induced by vaccination. CAR is an attachment receptor for both ChAdOx1 and Ad26 [42] and has been shown to be expressed on the platelet surface [35, 38, 43]. The αVβ3, and other integrins, are key secondary cell entry receptors which adenoviruses can attach to and are also present on the platelet surface [84]. Similarly, surface glycans have a strong negative charge which may be able to passively facilitate adenovirus localisation to the platelet surface [85]. Adenovirus binding has been demonstrated to drive platelet activation, platelet-leukocyte aggregate formation, and endothelial activation. It is tempting, therefore, to conclude that this is strong circumstantial evidence for a role of direct adenovirus binding to platelets in the formation of clots. However, it is known that once bound by adenoviruses, these platelets are cleared by liver Kupffer cells [86]. This has been observed to result in thrombocytopenia in a study of mice treated with intravenous adenovirus at a dose >7000X higher than the equivalent doses, by body weight, given in the vaccine [35, 38]. It should be noted that none of these animals developed blood clots despite the considerable level of adenovirus in the blood. A further study performed in Rhesus Macaques also observed thrombocytopenia, but not clotting, and noted that the adenovirus therapy resulted in longer clotting times [32, 87].

Nevertheless, if direct binding to platelets resulted in their activation and triggered a pro-thrombotic milieu, we might expect patients to present very shortly following vaccination, rather than after days to weeks as has been reported. It is well established that replication...
incompetent adenoviruses, such as ChAdOx1 nCoV-19 and Ad26.COV2.S, are rapidly cleared from the body, as are adenovirus bound platelets [35]. The earliest VITT events reported so far was 5 days post vaccination. Therefore, this is an unlikely direct explanation for VITT based on currently available evidence.

2- Adenovirus binding to coagulation factors and stimulate clot formation?
It is well established that certain adenoviruses, such as Ad5, bind to coagulation factor X (FX) [73-75]. This has been shown to facilitate an alternative mechanism of adenovirus infection via binding to heparan sulfate proteoglycans [74-76]. Previously unpublished data (now presented in supplemental figure 1) demonstrate that despite strong binding to the adenovirus, FX does not become activated. It has also previously been demonstrated that Ad26 does not engage FX, and ChAdOx1 does not share any of the key adenovirus/FX binding residues [74, 77, 88] and is thus unlikely to sequester FX. Also, as discussed above, a mechanism for VITT which is driven by the presence of adenovirus in the blood would present shortly following vaccination, rather than >5 days later.

3- “Vaccine Induced COVID-19 Mimicry”- the role of spike protein splice variants?
It was recently proposed that trace amounts of spike splice variant transcripts are produced via alternative splicing, resulting in C-terminally deleted mRNAs. These C-terminally deleted mRNAs could, if translated, result in soluble alternative spike isoforms being secreted into the extracellular space and leaked into the bloodstream [89]. As alternative splicing is a DNA specific phenomenon, this presents an alternative explanation as to why VITT is observed with adenovirus vectored vaccines, which encode the transgene as DNA, and not the lipid vector mRNA vaccines. In this model, the authors propose that spike protein binding ACE2 on endothelial cells may initiate vascular inflammation and damage with consequent platelet activation, initiating thrombotic events and PF4 release, characteristic of VITT [90]. The authors term this effect “Vaccine Induced COVID-19 Mimicry”. Since mRNA-based vaccines would, by definition, not require splicing, this would explain why this side effect is mediated specifically by adenoviral vectors and not mRNA-based vaccines. However, a previous study
evaluating the transcriptome of ChAdOx1 nCoV-19 infected A549 and MRC-5 lung cells failed to show any detectable levels of such a transcript, and it remains to be clarified whether this alternative transcript is translated into functional, secreted protein [91]. This proposed mechanism could be easily tested in mouse models using either IV delivery of SARS-CoV-2 free spike protein, and/or IM delivery of viral vectors engineered to only express soluble spike protein isoforms, to evaluate whether such treatments result in a VITT-like syndrome in human ACE2 transgenic animals. This proposed mechanism may account for some of the delay observed in the induction of VITT, as it would take 24-48hrs for the vaccination to begin producing maximal quantities of spike protein and the supposed soluble variant. Presumably the rest of the delay might be accounted for by rarity of soluble spike being presented on the cell surface long enough to encounter enough anti-spike antibodies and remain presented long enough to result in antibody dependent cell cytotoxicity (ADCC), as the study’s authors propose [89]. Further studies should also assess how long such a C-terminal truncated spike protein can remain attached to the surface of the ACE2 expressing cell, and at what rate it becomes internalised or degraded. A short half-life on the cell surface would reduce the probability of a pathogenic ADCC response. This mechanism would presuppose that VITT patients have pre-existing anti-spike antibodies to trigger ADCC in as early as 5-days post vaccination, as it would take longer to raise novel anti-spike antibodies without existing B-memory cells [92]. However, as previously discussed, a previous study has failed to demonstrate transcription of soluble SARS-CoV-2 spike from cells transduced with the vaccine [91]. Also, this mechanism fails to account for why all tested VITT patients are expressing anti-PF4 antibodies [5]. Finally, if this mechanism can induce clotting it might be expected to be more common than is observed as it would not seem to require any risk factors and could occur with equal likelihood in any member of the population.
4- Does adenovirus binding to PF4 promote misplaced anti-PF4 antibodies leading to (heparin independent) platelet activation?

Given that patients presenting with VITT appear to also present with significant anti-PF4 responses, an obvious start would be to investigate whether there are any interactions between PF4 and ChAdOx1/Ad26, which might prime a misplaced anti-PF4 response. Indeed, such a mechanism has been proposed by Greinacher and colleagues, whose recent TEM experiments suggest a direct interaction between ChAdOx1 and PF4 [91]. More recently still, Baker et al pre-printed the ~4 angstrom resolution structure of the ChAdOx1 viral capsid, and demonstrated putative binding of tetrameric PF4 between ChAdOx1 hexon proteins using computational simulations [65]. The authors suggest that ChAdOx1 capsid retains PF4 when the virus is taken up by monocytes and trafficked to the lymph nodes. They suggest that upon release of the adenovirus/PF4 complex into the lymph this may stimulate proliferation of pre-existing memory B cells against PF4, which have been previously observed in a minority of the population, contributing to instances of aHIT [8]. These strong antibodies, if released at a sufficient titre, could then aggregate PF4 in a ligand independent manner, as shown previously [9]. These IgG/PF4 complexes could then bind to FcγRIIa and stimulate platelet activation, and the clotting cascade, in a mechanism similar to aHIT [3]. In support of this idea is that VITT patients are known to present with strong, heparin independent, anti-PF4 antibodies [5]. If trafficked by association with the adenovirus there would not be any polyanions, such as heparin present, during B-cell stimulation. Therefore, the only memory B-cells stimulated would be heparin independent, as observed. Further, this mechanism pre-supposes the existence of anti-PF4 antibodies, a known phenomenon. This proposal, remains to be tested, also accounts for the timing of VITT, as 5 days post antigen exposure is within the timeframe for secondary antibody responses. One unanswered question is: why does VITT seem to occur only after the first dose and not the second? Further, a definite association between the adenovirus capsid and PF4, remains to be conclusively established via surface plasmon resonance and microscopy studies. Finally, additional experiments would be required to prove that an adenovirus/PF4 complex could be
trafficked to the lymph nodes where it could stimulate memory B cell proliferation and secondary immunity.

5- **Do anti-vector T cell responses play a role?**

ChAdOx1 and Ad26 were selected based on their very low seroprevalence rates in the community. However, it is feasible that pre-existing, cross-reactive T cell responses against prior adenovirus infections may provide help to B cells in the generation of anti-PF4 responses, following the formation of PF4-adenovirus complexes. To provide such helper functions, these T cell responses would be CD4+. Indeed, CD4+ T cells against species E chimpanzee adenovirus 63 (ChAd63) were measured at low pre-vaccination frequencies during clinical evaluation of ChAd63 as a malaria vaccine candidate and were boosted by vaccination [94]. Research into HIT suggests T cells could play such a helper role, with T cells to PF4-heparin complexes measured in HIT patients [95], and mouse studies demonstrating a necessary role for CD4+ T cells in the generation of PF4/heparin-specific antibodies in murine HIT [96].

The strong proinflammatory T cell responses induced by vaccination could also advantage the anti-PF4 antibody response in VITT, as IL-10 producing regulatory T cells have been demonstrated to suppress PF4/heparin-specific antibody responses during HIT in mice [97]. Research suggests HIT in humans has characteristics of both T-dependent and T-independent antibody production pathways [98, 99], with the role of T cells in VITT to still be elucidated. Future studies should aim to examine T cell responses against ChAdOx1: addressing the extent to which cross-reactive T cell responses from other adenovirus infections exist in the community; examining whether they are boosted by vaccination; and evaluating how they might contribute to VITT. One difficulty in addressing the latter is the lack of pre-vaccination PBMC specifically from VITT patients. Importantly, the timing of the T helper contribution fits with the onset of VITT, with pre-existing anti-vector T cells able to provide early help to B cells in the generation of anti-PF4 antibodies. Expanded populations of antigen-specific T cells are also measured within the first 7 days of vaccination [100]. The
potential role of anti-vector T cells in VITT, however, does not explain why VITT predominantly occurs after the first vaccination.

6- **Impurities in Vaccine Preparations?**

Another proposition states that it is possible that impurities of human proteins in vaccine preparation trigger autoantibodies. Biochemical and proteomic analysis of the ChAdOx1 nCov-19 showed both human and non-structural viral proteins such as heat-shock proteins and cytoskeletal proteins [100]. This proposal suggests that adenovirus acts as an adjuvant for the ~50% of human protein in the preparation, and autoantibodies against human membrane proteins from HEK293 cell contaminants during the process of adenovirus manufacture might be the source. Hence, it is possible that the differing frequencies with which VITT is observed might relate to the relative purities of the preparations in question. Recent work has shown that SARS-CoV-2 infection itself can also induce a diverse array of functional autoantibodies in the host [101] though their clinical implications are unclear. While in VITT the cause for platelet activation seems to be the PF4/IgG complexes, theoretically, any circulating autoantibody can do if in sufficient amounts. Thromboembolism remains an extremely rare side effect of COVID-19 vaccination. In the future, it will be important to profile auto antibody production resulting from SARS-CoV-2 infection and the proposed autoantibodies resulting from vaccination in order to establish any possible links between the presence of auto antibodies and thromboembolic events.

7- **SARS-CoV-2 induced (COVID-19) rather than VITT?**

Is it possible that some VITT patients would have been infected with SARS-CoV-2 immediately after adenoviral vectored vaccine administration and that the immune thrombosis in VITT is an atypical COVID-19 immune thrombosis? While this theory currently lacks evidence and is a somewhat a remote possibility, it is worth the discussion. Both SARS-CoV-2 infection and VITT appear to have several features in common with some differences (Table 1). They both feature platelet activation, thrombocytopenia- although in VITT, this is much more severe- and thrombosis, with the presence of PF4 antibodies -at
least in some COVID-19 patients. VITT presents more strongly than regular COVID-19. Thrombocytopenia has been documented in varying levels in COVID-19 and severe thrombocytopenia was considered a marker of severity of disease and mortality [102, 46]. The concept of COVID-19 induced Coagulopathy (CAC) has helped understand the pathology and diagnosis of the predominantly procoagulant state in COVID-19 [103-105] but the pathological focus was on thrombin generation -rather than primarily platelet activation- as a trigger for thrombosis. But perhaps COVID coagulopathy is primarily triggered by platelet activation that then stimulate thrombin generation. It is possible that SARS-CoV-2 spike protein binds to the ACE2 receptor on platelets although it is debatable whether or not platelets have the ACE2 receptor [106]. There is also the potential that adenovirus binds to αIIbβ3 via its RGD domain. Antibodies to spike protein can induce platelet activation in COVID-19 patients in a FcyRIIa-dependent manner [107] and blocking of this by COVID-19 plasma prevented this activation in vitro [108]. Activated platelet release ADP and PF4, microparticles in COVID-19 patients [2]. We know all VITT patients have anti-PF4 antibodies despite no history of heparin exposure [109, 110]. We also know 0.3-5% of the normal population have anti-PF4 antibodies. High levels of PF4 and anti-PF4 antibodies were reported in COVID-19 patients [111]. An important treatment for both HIT and for VITT is intravenous IgG (IVIg) is a known inhibitor of FcyRIIa. PCR testing has shown negative SARS CoV2 infection in many but not all VITT patients. Whether VITT is an atypical form of COVID-19 requires further studies.

Concluding Remarks

The primary and downstream mechanisms underlying VITT phenomenon remain to be completely elucidated. Here, we have discussed and critiqued the potential mechanisms in relation to adenovirus induction of VITT. Whilst it is not possible yet to pinpoint the direct pathogenic mechanism(s) underpinning VITT, it is worthwhile to explore the possible evidence in relation to what is known around adenovirus immunogenicity and interactions with platelets and other host proteins, as well as the role of PF4 and platelet activation. We overviewed these proposed “smoking guns” that could underlie VITT in Figure 1. While it is
challenging to agree on a singular model at this point, we have attempted to provide clues on areas warranting further investigation into the mechanistic basis of VITT and to highlight the unanswered questions. We appeal for immediate and urgent further investigation into each of these questions to solidify a pathogenic model for this condition. This understanding will facilitate condition specific clinical guidance for the treatment of this condition and will inform how adenovirus-based vaccines might be further developed and improved to enhance their otherwise impressive safety profile.

Addendum:
MO and AP developed the concept and synthesized the plan for the manuscript. All authors contributed intellectually to the manuscript, critiqued the mechanisms presented, wrote various sections, reviewed, and approved the manuscript.

References

1. See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT, Talaat KR, Urrutia VC, Walker SC, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA 2021; 325: 2448–56.

2. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine Massachusetts Medical Society; 2021; 384: 2202–11.

3. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15: 2099–114.

4. Baglin TP. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. Journal of Clinical Pathology 2001; 54: 272–4.
5. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med* 2021; 384: 2092–101.

6. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt A-H, Skattør TH, Tjønnfjord GE, Holme PA. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021; 384: 2124–30.

7. Mohanty E, Nazir S, Sheppard J-Al, Forman DA, Warkentin TE. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome. *J Thromb Haemost* 2019; 17: 841–4.

8. Warkentin TE, Makris M, Jay RM, Kelton JG. A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia. *The American Journal of Medicine* Elsevier; 2008; 121: 632–6.

9. Nguyen T-H, Medvedev N, Delcea M, Greinacher A. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. *Nat Commun* 2017; 8: 14945.

10. Brodard J, Hovinga JAK, Fontana P, Studt J-D, Gruel Y, Greinacher A. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. *Journal of Thrombosis and Haemostasis* 2021; 19: 1294–8.

11. Inc MG. ISTH Interim Guidance for the Diagnosis and Treatment on... by. *ISTH Academy*. 2021.

12. Holder J. Tracking Coronavirus Vaccinations Around the World. *The New York Times*.

13. Cines DB, Bussel JB. SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. *n engl j med* 2021; : 3.

14. Italy Reported Four Clot Deaths After AstraZeneca Shots, Data Shows | World News | US News. *US News & World Report*.

15. Administration AGD of HTG. COVID-19 vaccine weekly safety report - 20-05-2021. *Therapeutic Goods Administration (TGA)*. Australian Government Department of Health; 2021.
16. News · JPT · C. Canada reports 28 cases of rare blood clots following AstraZeneca vaccinations | CBC News. CBC. 2021.

17. Chan B, Odutayo A, Juni P, Stall NM, Bobos P, Brown AD, Grill A, Ivers N, Maltsev A, McGeer A, Miller KJ, Niel U, Razak F, Sander B, Sholzberg M, Slutsky AS, Morris AM, Pai M. Risk of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) following the AstraZeneca/COVISHIELD Adenovirus Vector COVID-19 Vaccines. Ontario COVID-19 Science Advisory Table; 2021 May.

18. Coronavirus vaccine - weekly summary of Yellow Card reporting. GOV.UK.

19. Coronavirus (COVID-19) Vaccinations - Statistics and Research. Our World in Data

20. Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, McCowan C, Agrawal U, Shah SA, Ritchie LD, Murray J, Pan J, Bradley DT, Stock SJ, Wood R, Chuter A, Beggs J, Stagg HR, Joy M, Tsang RSM, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med 2021; .

21. Lee E, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, Semple JW, Arnold DM, Godeau B, Lambert MP, Bussel JB. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021; : 10.1002/ajh.26132.

22. Coughlan, L., Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. Front Immunol, 2020. 11: p. 909.

23. Kallel, H. and A.A. Kamen, Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. Biotechnol J, 2015. 10(5): p. 741-7.

24. Krause, A. and S. Worgall, Delivery of antigens by viral vectors for vaccination. Ther Deliv, 2011. 2(1): p. 51-70.

25. Watkins, D.I., et al., Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med, 2008. 14(6): p. 617-21.

26. Patterson, L.J., The "STEP-wise" future of adenovirus-based HIV vaccines. Curr Med Chem, 2011. 18(26): p. 3981-6.

27. Koblin, B.A., et al., Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a
randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr, 2012. 60(4): p. 405-13.

28. Matz, K.M., A. Marzi, and H. Feldmann, Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines, 2019. 18(12): p. 1229-1242.

29. Morris, S.J., et al., Simian adenoviruses as vaccine vectors. Future Virol, 2016. 11(9): p. 649-659.

30. Antrobus, R.D., et al., Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther, 2014. 22(3): p. 668-674.

31. Mutua, G., et al., Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. J Infect Dis, 2019. 220(1): p. 57-67.

32. Lozier JN, Csako G, Mondoro TH, Krizek D m., Metzger ME, Costello R, Vostal JG, Rick M e., Donahue RE, Morgan RA. Toxicity of a First-Generation Adenoviral Vector in Rhesus Macaques. Human Gene Therapy Mary Ann Liebert, Inc., publishers; 2002; 13: 113–24.

33. Cichon G, Schmidt HH, Benhidjeb T, Löser P, Ziemer S, Haas R, Grewe N, Schnieders F, Heeren J, Manns MP, Schlag PM, Strauss M. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. The Journal of Gene Medicine 1999; 1: 360–71.

34. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized mice. Gene Ther 2005; 12: 427–36.

35. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2006; 109: 2832–9.

36. Assinger A. Platelets and Infection – An Emerging Role of Platelets in Viral Infection. Front Immunol 2014; 5: 649.
37. Raadsen M, Du Toit J, Langerak T, van Bussel B, van Gorp E, Goeijenbier M. Thrombocytopenia in Virus Infections. *Journal of Clinical Medicine* Multidisciplinary Digital Publishing Institute; 2021; **10**: 877.

38. Stone D, Liu Y, Shayakhmetov D, Li Z-Y, Ni S, Lieber A. Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver. *J Virol* 2007; **81**: 4866–71.

39. Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. *Thromb Haemost* 2001; **86**: 214–21.

40. Gupalo E, Kuk C, Qadura M, Buriachkovskaia L, Othman M. Platelet-adenovirus vs. inert particles interaction: effect on aggregation and the role of platelet membrane receptors. *Platelets* 2013; **24**: 383–91.

41. Jin Y-Y, Yu X-N, Qu Z-Y, Zhang A-A, Xing Y-L, Jiang L-X, Shang L, Wang Y-C. Adenovirus type 3 induces platelet activation in vitro. *Molecular Medicine Reports* Spandidos Publications; 2014; **9**: 370–4.

42. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5. *Science* American Association for the Advancement of Science; 1997; **275**: 1320–3.

43. Gupalo, E.; Buriachkovskaia, L.; Othman, M. Human platelets express CAR with localization at the sites of intercellular interaction. Virol. J. 2011, 8, 456.

44. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. *Cell* Elsevier; 1993; **73**: 309–19.

45. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. *J Cell Biol* 1994; **127**: 257–64.

46. Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. *Platelets* 2020; **31**: 740–5.
47. Zhang Y, Bergelson JM. Adenovirus Receptors. *Journal of Virology* American Society for Microbiology; 2005; 79: 12125–31.

48. Escutenaire, S.; Cerullo, V.; Diaconu, I.; Ahtiainen, L.; Hannuksela, P.; Oksanen, M.; Haavisto, E.; Karioja-Kallio, A.; Holm, S.L.; Kangasniemi, L.; et al. In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. *Ann. Med.* 2011, 43, 151–163.

49. Dicks, M.D., et al., A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. *PLoS One*, 2012. 7(7): p. e40385.

50. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. *Biotechnology* 1992; 20: 363–90.

51. Borkenhagen LK, Fieldhouse JK, Seto D, Gray GC. Are adenoviruses zoonotic? A systematic review of the evidence. *Emerg Microbes Infect* 2019; 8: 1679–87.

52. Chen EC, Yagi S, Kelly KR, Mendoza SP, Maninger N, Rosenthal A, Spinner A, Bales KL, Schnurr DP, Lerche NW, Chiu CY. Cross-Species Transmission of a Novel Adenovirus Associated with a Fulminant Pneumonia Outbreak in a New World Monkey Colony. *PLoS Pathog* 2011; 7.

53. Ludwig, S.L., et al., Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. *J Infect Dis*, 1998. 178(6): p. 1776-8.

54. Gooch, W.M., 3rd and W.J. Mogabgab, Simultaneous oral administration of live adenovirus types 4 and 7 vaccines. Protection and lack of emergence of other types. *Arch Environ Health*, 1972. 25(6): p. 388-94.

55. van der Veen, J., M.F. Abarbanel, and K.G. Oei, Vaccination with live type 4 adenovirus: evaluation of antibody response and protective efficacy. *J Hyg (Lond)*, 1968. 66(4): p. 499-511.

56. Gurwith, M., et al., Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. *Lancet Infect Dis*, 2013. 13(3): p. 238-50.
57. Emergent BioSolutions. Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn. clinicaltrials.gov; 2020 Mar. Report No.: NCT01006798.

58. National Institute of Allergy and Infectious Diseases (NIAID). Phase 1 Study of Safety and Immunogenicity of Intranasal Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers. clinicaltrials.gov; 2019 Oct. Report No.: NCT01806909.

59. Emergent BioSolutions. A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen) and Ad4-PA-GPI (Glycosylphosphatidylinositol). clinicaltrials.gov; 2020 Mar. Report No.: NCT01979406.

60. National Institute of Allergy and Infectious Diseases (NIAID). Phase I Open-Label Study of Safety and Immunogenicity of AD4-HIV Envelope Vaccine Vectors in Healthy Volunteers. clinicaltrials.gov; 2020 Dec. Report No.: NCT03878121.

61. Emergent BioSolutions. A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Orally-administered Replication-competent Adenovirus Type-4 HIV Vaccine Regimens in Combination With an AIDSVAX® B/E Boost in Healthy, HIV-uninfected Adult Participants. clinicaltrials.gov; 2018 Jul. Report No.: NCT02771730.

62. Imperial College London. A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus. clinicaltrials.gov; 2020 Feb. Report No.: NCT03408262.

63. Martino, T.A., et al., The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus. Virology, 2000. 271(1): p. 99-108.

64. Dicks, M.D., et al., Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Sci Rep, 2015. 5: p. 16756.
65. Baker, A.T., et al., The Structure of ChAdOx1/AZD-1222 Reveals Interactions with CAR and PF4 with Implications for Vaccine-induced Immune Thrombotic Thrombocytopenia. bioRxiv, 2021: p. 2021.05.19.444882.
66. Li, H., et al., Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol, 2012. 86(19): p. 10862-5.
67. Persson BD, John L, Rafie K, Strebl M, Frängsmyr L, Ballmann MZ, Mindler K, Havenga M, Lemckert A, Stehle T, Carlson L-A, Arnberg N. Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46. Proc Natl Acad Sci U S A 2021; 118: e2020732118.
68. Baker, A.T., et al., Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nat Commun, 2019. 10(1): p. 741.
69. Baker, A.T., et al., Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor. Sci Adv, 2019. 5(9): p. eaax3567.
70. Chandra, N., et al., Sialic Acid-Containing Glycans as Cellular Receptors for Ocular Human Adenoviruses: Implications for Tropism and Treatment. Viruses, 2019. 11(5).
71. Nestić, D., et al., αvβ3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26. J Virol, 2019. 93(1).
72. Albinsson, B. and A.H. Kidd, Adenovirus type 41 lacks an RGD alpha(v)-integrin binding motif on the penton base and undergoes delayed uptake in A549 cells. Virus Res, 1999. 64(2): p. 125-36.
73. Parker, A.L., et al., Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 2006. 108(8): p. 2554-61.
74. Waddington, S.N., et al., Adenovirus serotype 5 hexon mediates liver gene transfer. Cell, 2008. 132(3): p. 397-409.
75. Kalyuzhniy, O., et al., Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A, 2008. 105(14): p. 5483-8.
76. Parker, A.L., et al., Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol, 2009. 83(1): p. 479-83.
77. Alba, R., et al., Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 2009. 114(5): p. 965-71.

78. Irons EE, Flatt JW, Doronin K, Fox TL, Acchione M, Stewart PL, Shayakhmetov DM. Coagulation Factor Binding Orientation and Dimerization May Influence Infectivity of Adenovirus-Coagulation Factor Complexes. J Virol 2013; 87: 9610–9.

79. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, Kemball-Cook G, Ni S, Lieber A, McVey JH, Nicklin SA, Baker AH. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006; 108: 2554–61.

80. Duffy MR, Bradshaw AC, Parker AL, McVey JH, Baker AH. A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes. J Virol 2011; 85: 10914–9.

81. Shiri, A., Sarvari, J., Firooz Ghahestani, S. et al. The Inflammatory and Fibrotic Patterns of Hepatic Stellate Cells Following Coagulation Factors (VII or X)-Shielded Adenovirus Infection. Curr Microbiol 78, 718–726 (2021).

82. Jiang, H., et al., Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther, 2004. 10(6): p. 1140-2.

83. Carlisle, R.C., et al., Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009. 113(9): p. 1909-18.

84. Huang, J., et al., Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol, 2019. 12(1): p. 26.

85. Trimaille, A., Curtiaud, A., Marchandot, B., Matsushita, K., Sato, C., Leonard-Lorant, I., et al. (2020).Venous thromboembolism in non-critically ill patients with COVID-19 infection. Thrombosis Research 193, 166-169.

86. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. Journal of General Virology 2000; 81: 2605–9.
87. Bradshaw AC, Parker AL, Duffy MR, Coughlan L, Rooijen N van, Kähäri V-M, Nicklin SA, Baker AH. Requirements for Receptor Engagement during Infection by Adenovirus Complexed with Blood Coagulation Factor X. *PLOS Pathogens* Public Library of Science; 2010; 6: e1001142.

88. Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, Waddington SN, Buckley SMK, Greig JA, Parker AL, Miller AM, Wang H, Lieber A, van Rooijen N, McVey JH, Nicklin SA, Baker AH. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. *Blood* 2010; 116: 2656–64.

89. Kowarz E, Krutzke L, Reis J, Bracharz S, Kochanek S, Marschalek R. “Vaccine-Induced Covid-19 Mimicry” Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines. In Review; 2021 May.

90. Krutzke L, Roesler R, Wiese S, Kochanek S. Process-related impurities in the ChAdOx1 nCov-19 vaccine. In Review; 2021 May.

91. Almuqrin A, Davidson AD, Williamson MK, Lewis PA, Heesom KJ, Morris S, Gilbert SC, Matthews DA. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. *Genome Medicine* 2021; 13: 43.

92. Murphy KM, Weaver C, Mowat A, Berg L, Chaplin D, Janeway CA, Travers P, Walport M. Janeway’s immunobiology. 2017.

93. Greinacher A, Selleng K, Wesche J, Handtke S, Palankar R, Aurich K, Lalk M. Towards Understanding ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). : 13.

94. Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, de Cassan SC, Grobbelaar A, Lawrie AM, Venkatraman N, Poulton ID, Roberts R, Mange PB, Choudhary P, Faust SN, Colloca S, Gilbert SC, Nicosia A, Hill AVS, Ewer KJ. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. *Sci Rep* 2018; 8: 3390.
95. Bacsi S, Geoffrey R, Visentin G, De Palma R, Aster R, Gorski J. Identification of T
cells responding to a self-protein modified by an external agent. *Human Immunology*
2001; 62: 113–24.

96. Zheng Y, Yu M, Padmanabhan A, Aster RH, Yuan L, Wen R, Wang D. Critical role of
CD4 T cells in PF4/heparin antibody production in mice. *Blood* 2015; 125: 1826–9.

97. Zheng, Y., et al., Regulatory T Cells Control PF4/Heparin Antibody Production in
Mice. J Immunol, 2019. 203(7): p. 1786-1792.

98. Khandelwal, S. and G.M. Arepally, Immune pathogenesis of heparin-induced
thrombocytopenia. Thromb Haemost, 2016. 116(5): p. 792-798.

99. Staibano, P., et al., The unique immunological features of heparin-induced
thrombocytopenia. British Journal of Haematology, 2017. 177(2): p. 198-207.

100. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R,
Flaxman A, Wright D, Bellamy D, Bittaye M, Dold C, Provine NM, Aboagye J, Fowler
J, Silk SE, Alderson J, Aley PK, Angus B, Berrie E, Bibi S, et al. T cell and antibody
responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a
phase 1/2 clinical trial. *Nat Med* 2021; 27: 270–8.

101. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow
B, Wong P, Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer
S, Campbell M, Fournier JB, et al. Diverse functional autoantibodies in patients with
COVID-19. *Nature* Nature Publishing Group; 2021; : 1–6.

102. Bomhof G, Mutsaers PGNJ, Leebeek FWG, Te Boekhorst PAW, Hofland J,
Croles FN, Jansen AJG. COVID-19-associated immune thrombocytopenia. *Br J
Haematol* 2020; 190: e61–4.

103. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique
characteristics of COVID-19 coagulopathy. *Crit Care* 2020; 24: 360.

104. Chen B, Jiang C, Han B, Guan C, Fang G, Yan S, Wang K, Liu L, Conlon CP,
Xie R, Song R. High prevalence of occult thrombosis in cases of mild/moderate
COVID-19. *Int J Infect Dis* 2021; 104: 77–82.
105. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of Thrombosis and Haemostasis* 2020; 18: 1094–9.

106. Campbell RA, Boilard E, Rondina MT. Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets? *J Thromb Haemost* 2021; 19: 46–50.

107. Apostolidis SA, Sarkar A, Giannini HM, Goel D, Mathew D, Suzuki A, Baxter AE, Greenplate AR, Alanio C, Abdel-Hakeem M, Oldridge DA, Giles J, Wu JE, Chen Z, Huang YJ, Pattekar A, Manne S, Kuthuru O, Dougherty J, Weiderhold B, et al. Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19. *bioRxiv* Cold Spring Harbor Laboratory; 2021; : 2021.05.01.442279.

108. Cappellano G, Raineri D, Rolla R, Giordano M, Puricelli C, Vilardo B, Manfredi M, Cantaluppi V, Sainaghi PP, Castello L, De Vita N, Scotti L, Vaschetto R, Dianzani U, Chiocchetti A. Circulating Platelet-Derived Extracellular Vesicles Are a Hallmark of Sars-Cov-2 Infection. *Cells* Multidisciplinary Digital Publishing Institute; 2021; 10: 85.

109. Muir K-L, Kallam A, Koepsell SA, Gundabolu K. Thrombotic Thrombocytopenia after Ad26.COVD2.S Vaccination. *New England Journal of Medicine* Massachusetts Medical Society; 2021; .

110. Cai Z, Greene MI, Zhu Z, Zhang H. Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19. *Antibodies (Basel)* 2020; 9: 52.

111. Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D’ambrozie J, Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M, Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. *CR Med* Elsevier; 2021; 2.
**Table 1: Comparison between COVID-19 and VITT**

|                         | VITT                                      | COVID-19                        |
|-------------------------|-------------------------------------------|---------------------------------|
| **Presentation**        | - Acute condition                        | - Acute condition               |
|                         | - 4 to 28 days after receiving           | - 2-14 days after exposure to   |
|                         | adenoviral COVID-19 vaccine              | SARS-CoV2 infection             |
|                         | - Stronger                                | - Less strong                   |
| **Platelet activation** | - Yes                                     | - Yes                           |
| **Thrombosis**          | - Yes                                     | - Yes                           |
|                         | - Venous and arterial sites              | - Venous and arterial sites     |
|                         | - Commonly CVS, splanchnic vein          |                                 |
|                         | thromboses                               |                                 |
|                         | - Other sites: DVT, PE,                  |                                 |
|                         | internal jugular, portal, aorto-iliac,   |                                 |
|                         | ilio-femoral veins                       |                                 |
|                         | - Multiple organ thrombi in brain,       |                                 |
|                         | lungs and kidneys                        |                                 |
| **PF4 ELISA**           | - Positive (all)                         | - Some are positive             |
| Condition          | Almost all cases | Not in all cases |
|--------------------|------------------|------------------|
| - Usually severe but variable levels reported | - Variable levels | - Usually in severe disease |
| - Acute            | - Some patients have elevated count | |

| Condition          | Markedly elevated | Markedly elevated in severe cases, ARDS or those with poor prognosis |
|--------------------|-------------------|---------------------------------------------------------------------|
| D-Dimer            |                   |                                                                     |

| Condition          | Elevated | Elevated early |
|--------------------|----------|----------------|
| - Reduced later in the disease |          | |

| Condition          | Has not been reported | Has been reported |
|--------------------|-----------------------|-------------------|
| DIC                |                       |                   |

| Condition          | No | Yes |
|--------------------|----|-----|
| Multiple organ failure |   |     |

| Condition          | No | Yes |
|--------------------|----|-----|
| Heparin exposure   |    |     |

| Condition          | Yes, first line of treatment | Not likely |
|--------------------|------------------------------|------------|
| IVIg use           |                              |            |

**Figure 1: The seven “smoking guns” of VITT.** Possible mechanisms of how adenoviral vectors may cause rare VITT. 1: Adenovirus leaks into blood stream following intramuscular injection of the vaccine, directly binds to platelet via CAR, and/or secondary receptors present on platelet, inducing platelet activation and triggering coagulation as well as liver clearance of activated platelets and thrombocytopenia. 2. The binding of adenovirus to coagulation factors such as FX, their potential activation thus triggering clot formation. 3.
“Vaccine induced COVID mimicry” resulting from vaccine induced secretion of mis-spliced, C terminal truncated spike protein into the blood, activating endothelial cells through ACE2. This initiates vascular inflammation and damage with consequent platelet activation, thrombotic events and PF4 release. 4. Binding of adenovirus capsid to PF4. The adenovirus/PF4 complex, stimulates pre-existing memory B cells against PF4, the IgG/PF4 complexes then binds to FcγRIIa and stimulates platelet activation, and clot formation. 5. PF4-adenovirus complexes are internalized by B cells that recognise PF4. These B cells present adenoviral peptides via MHC class II, which are recognised pre-existing anti-vector CD4+ T cells that in turn provide T cell help to B cells, and drive their production of anti-PF4 antibodies that can stimulate platelets via FcγRIIa. 6. Impurities of human or non-structural viral proteins in vaccine preparation triggering autoantibodies such as anti-PF4 which stimulates platelet activation, and clot formation. 7. Acute infection with SARS-CoV-2 following vaccine administration, modified/atypical COVID-19, presented with thrombosis and thrombocytopenia.

Supplemental Figure 1: Binding of FX to adenovirus type 5 does not result in FX activation. To assess whether binding of FX to Ad5 could result in the direct conversion of FX to activated FX (FXa), we performed a dose response of Ad5 and FX. We maintained either a standard concentration of FX (1000ng/ml) and varied the virus concentration from $10^1 – 10^9$ viral particles (vp), or a standard concentration of Ad5 ($10^7$vp) whilst varying the concentration of FX (50 – 5000 ng/ml) (A). To evaluate whether conversion of FX to FXa was enhanced by binding to Ad5 in the presence of cofactors tissue factor and +/- FVII, we performed additional studies on HepG2 cells (to provide a source of tissue factor) and FVII. The presence or absence of virus (indicated in red) did not enhance conversion of FX to FXa above levels observed in the same conditions but in the absence of virus (B). In both cases, a standard curve of FXa is shown as a positive control and to quantify for any conversion of FX to FXa observed.
5. Anti-vector T cell responses provide help to anti-PF4 B cells

6. Impurities in vaccine preparation triggering anti-PF4

7. SARS-CoV-2 induced (COVID-19) rather than VITT

4. Adenovirus binding to PF4 promotes anti-PF4 antibodies and platelet activation

1. Direct activation of platelets after entry of adenovirus into blood

3. The role of spike protein splice variants

2. Adenovirus binding to coagulation factors and stimulating clot formation

---

Dendritic cell  
Clot  
Inactive platelet  
Activated platelet  
Vaccine impurities  
PP4  
T-cell  
Kupffer cell  
SARS-CoV2  
Truncated soluble spike  
Spike  
Antibody  
Lymph node  
SARS-CoV2  
Adenovirus  
Liver

jth_15485_f1.jpeg

This article is protected by copyright. All rights reserved